secwatch / observer
8-K filed January 29, 2024, 6:59 PM ET ticker ABT CIK 0000001800
debt confidence high sentiment neutral materiality 0.25

ABBOTT LABORATORIES (ABT): debt financing — Abbott enters new $5B unsecured revolving credit facility, terminates prior facility

ABBOTT LABORATORIES

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ABBOTT LABORATORIES incurred revolving credit of up to $5 billion with JPMorgan Chase Bank, N.A. at SOFR rate, plus an applicable margin maturing fifth anniversary of the Effective Date.

Instrument
revolving credit
Principal
up to $5 billion
Counterparty
JPMorgan Chase Bank, N.A.
Rate
SOFR rate, plus an applicable margin
Maturity
fifth anniversary of the Effective Date
Event
incurrence
Exact text from the filing
lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent. The Revolving Credit Agreement provides Abbott with the ability to borrow up to $5 billion on an unsecured basis. Any borrowings under the Revolving Credit Agreement will mature and be payable on the fifth anniversary of the Effective Date. As of the date of this
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ABBOTT LABORATORIES entered into Five Year Credit Agreement with JPMorgan Chase Bank, N.A. valued at $5 billion unsecured borrowing capacity (effective 2024-01-29).

Action
entry
Agreement
credit facility
Counterparty
JPMorgan Chase Bank, N.A.
Value
$5 billion unsecured borrowing capacity
Effective
2024-01-29
Exact text from the filing
On January 29, 2024 (the “ Effective Date ”), Abbott Laboratories, an Illinois corporation (“ Abbott ”), entered into a Five Year Credit Agreement (the “ Revolving Credit Agreement ”) with the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

ABBOTT LABORATORIES terminated Five Year Credit Agreement, dated as of November 12, 2020 with JPMorgan Chase Bank, N.A. valued at Terminated all commitments; no outstanding borrowings (effective 2024-01-29).

Action
termination
Agreement
credit facility
Counterparty
JPMorgan Chase Bank, N.A.
Value
Terminated all commitments; no outstanding borrowings
Effective
2024-01-29
Exact text from the filing
In connection with its entry into the Revolving Credit Agreement, on the Effective Date Abbott terminated all commitments outstanding under the Five Year Credit Agreement, dated as of November 12, 2020 (as amended by that certain Amendment No. 1, dated as of May 12, 2023, the “ Existing Credit Agreement ”), among Abbott, the lenders from time to time party thereto and JPMorgan Chase Bank, N.A., as administrative agent.
View on SEC.gov

283 debt financings filed in the last 30 days. Browse all debt financings →

ABBOTT LABORATORIES filing history →

Source: SEC EDGAR
accession 0001104659-24-007725
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.